{"id":21,"date":"2026-08-17T12:53:22","date_gmt":"2026-08-17T12:53:22","guid":{"rendered":"https:\/\/peptide-doc.com\/learn\/cjc-1295\/"},"modified":"2026-09-02T19:41:50","modified_gmt":"2026-09-02T19:41:50","slug":"cjc-1295","status":"publish","type":"learn_article","link":"https:\/\/peptide-doc.com\/de\/learn\/cjc-1295\/","title":{"rendered":"CJC-1295"},"content":{"rendered":"<div class=\"placeholder-meta\">\n<strong>META-TITLE:<\/strong> [TODO: CJC-1295 \u2014 Extended GHRH Research Profile | Brand]<br \/>\n<strong>META-DESC:<\/strong> [TODO: CJC-1295 research overview \u2014 DAC vs no-DAC variants, extended half-life GHRH, GH secretion, dosing protocols.]\n<\/div>\n<p><span class=\"todo\">[TODO]<\/span> Hook \u2014 CJC-1295 as the next-generation GHRH analog, Drug Affinity Complex for extended half-life, two variants in research<\/p>\n<div class=\"placeholder-img\">[IMAGE: CJC-1295 molecular structure \u2014 modified GHRH(1-29) with DAC conjugation]<\/div>\n<h2>What is CJC-1295?<\/h2>\n<ul>\n<li><span class=\"todo\">[TODO]<\/span> Classification \u2014 modified GHRH(1-29) analog with amino acid substitutions for DPP-4 resistance<\/li>\n<li><span class=\"todo\">[TODO]<\/span> Two variants \u2014 CJC-1295 with DAC (Drug Affinity Complex) vs CJC-1295 no DAC (Mod GRF 1-29)<\/li>\n<li><span class=\"todo\">[TODO]<\/span> DAC \u2014 maleimidoproprionic acid linker, binds albumin, extends half-life to 6-8 days<\/li>\n<li><span class=\"todo\">[TODO]<\/span> No-DAC (Mod GRF 1-29) \u2014 half-life ~30 minutes, more pulsatile GH release<\/li>\n<li><span class=\"todo\">[TODO]<\/span> Developer \u2014 ConjuChem Biotechnologies<\/li>\n<\/ul>\n<h2>Mechanism of Action<\/h2>\n<ul>\n<li><span class=\"todo\">[TODO]<\/span> Same GHRH receptor target as sermorelin \u2014 anterior pituitary somatotrophs<\/li>\n<li><span class=\"todo\">[TODO]<\/span> DAC variant \u2014 sustained GH elevation over days, &#8220;GH bleed&#8221; rather than pulse<\/li>\n<li><span class=\"todo\">[TODO]<\/span> No-DAC variant \u2014 preserves pulsatile GH pattern, often combined with GHRP<\/li>\n<li><span class=\"todo\">[TODO]<\/span> DPP-4 resistant \u2014 4 amino acid substitutions prevent enzymatic degradation<\/li>\n<\/ul>\n<h2>Research Highlights<\/h2>\n<ul>\n<li><span class=\"todo\">[TODO]<\/span> GH levels \u2014 DAC variant: 2-10x GH increase sustained for days<\/li>\n<li><span class=\"todo\">[TODO]<\/span> IGF-1 \u2014 significant elevation in clinical studies with both variants<\/li>\n<li><span class=\"todo\">[TODO]<\/span> Body composition \u2014 lean mass increases, fat mass reduction in animal models<\/li>\n<li><span class=\"todo\">[TODO]<\/span> Synergy \u2014 Mod GRF 1-29 + Ipamorelin = amplified GH pulse (popular research combo)<\/li>\n<\/ul>\n<h2>Dosing Protocols (Research Context)<\/h2>\n<ul>\n<li><span class=\"todo\">[TODO]<\/span> CJC-1295 DAC \u2014 1-2mg once or twice weekly (subcutaneous)<\/li>\n<li><span class=\"todo\">[TODO]<\/span> Mod GRF 1-29 (no DAC) \u2014 100mcg 2-3x daily, before meals or before bed<\/li>\n<li><span class=\"todo\">[TODO]<\/span> Combination \u2014 Mod GRF + Ipamorelin at 100mcg each, pre-bed<\/li>\n<li><span class=\"todo\">[TODO]<\/span> Storage \u2014 standard peptide reconstitution, 2-8\u00b0C<\/li>\n<\/ul>\n<h2>Safety &amp; Considerations<\/h2>\n<ul>\n<li><span class=\"todo\">[TODO]<\/span> DAC variant \u2014 concern about non-physiological sustained GH elevation<\/li>\n<li><span class=\"todo\">[TODO]<\/span> Side effects \u2014 water retention, numbness\/tingling (paresthesia), headache<\/li>\n<li><span class=\"todo\">[TODO]<\/span> No-DAC preferred \u2014 more researchers prefer pulsatile pattern for safety<\/li>\n<li><span class=\"todo\">[TODO]<\/span> Cortisol\/prolactin \u2014 minimal effect (advantage over GHRP-6)<\/li>\n<\/ul>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"placeholder-faq\">[FAQ: What is the difference between CJC-1295 with DAC and without DAC?]<\/div>\n<div class=\"placeholder-faq\">[FAQ: Why is Mod GRF 1-29 often combined with Ipamorelin?]<\/div>\n<div class=\"placeholder-faq\">[FAQ: How does CJC-1295 compare to Sermorelin?]<\/div>\n<div class=\"placeholder-faq\">[FAQ: Can food intake affect the GH response?]<\/div>\n<h2>Related Products<\/h2>\n<p><span class=\"todo\">[TODO]<\/span> Link to CJC-1295 product page + Growth Hormone category<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[META-DESC TODO: CJC-1295 research profile \u2014 modified GHRH, DAC vs no-DAC, extended GH release, protocols.]<\/p>\n","protected":false},"featured_media":0,"template":"","learn_category":[4],"class_list":["post-21","learn_article","type-learn_article","status-publish","hentry","learn_category-growth-hormone"],"_links":{"self":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article\/21","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article"}],"about":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/types\/learn_article"}],"version-history":[{"count":1,"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article\/21\/revisions"}],"predecessor-version":[{"id":44,"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article\/21\/revisions\/44"}],"wp:attachment":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/media?parent=21"}],"wp:term":[{"taxonomy":"learn_category","embeddable":true,"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_category?post=21"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}